Overview

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

Status:
Withdrawn

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of inhaled formoterol fumarate (7.2 and 9.6 µg ex-actuator) compared to placebo and Foradil Aerolizer in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Phase:

Phase 2

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Formoterol Fumarate